TScan Therapeutics inks $100m Series C
TScan Therapeutics, a developer of T-cell receptor engineered T cell therapies in oncology, has raised $100 million in Series C financing.
TScan Therapeutics, a developer of T-cell receptor engineered T cell therapies in oncology, has raised $100 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination
